3724-26-3Relevant articles and documents
-
Alley
, p. 1837 (1975)
-
Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A2AReceptor
Amelia, Tasia,Van Veldhoven, Jacobus P. D.,Falsini, Matteo,Liu, Rongfang,Heitman, Laura H.,Van Westen, Gerard J. P.,Segala, Elena,Verdon, Grégory,Cheng, Robert K. Y.,Cooke, Robert M.,Van Der Es, Daan,Ijzerman, Adriaan P.
, p. 3827 - 3842 (2021/05/04)
In this study, we determined the crystal structure of an engineered human adenosine A2A receptor bound to a partial agonist and compared it to structures cocrystallized with either a full agonist or an antagonist/inverse agonist. The interaction between the partial agonist, belonging to a class of dicyanopyridines, and amino acids in the ligand binding pocket inspired us to develop a small library of derivatives and assess their affinity in radioligand binding studies and potency and intrinsic activity in a functional, label-free, intact cell assay. It appeared that some of the derivatives retained the partial agonist profile, whereas other ligands turned into inverse agonists. We rationalized this remarkable behavior with additional computational docking studies.
3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE
-
Page/Page column 200, (2015/03/28)
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, e
Non-benzimidazole containing inhibitors of respiratory syncytial virus
Pryde, David C.,Tran, Thien-Duc,Gardner, Iain,Bright, Helen,Stupple, Paul,Galan, Sebastien,Alsop, Liam,Watson, Lesa,Middleton, Donald S.,Dayal, Satish,Platts, Michelle,Murray, Edward J.,Parkinson, Tanya,Webster, Robert
supporting information, p. 827 - 833 (2013/03/13)
Several non-benzimidazole containing inhibitors of respiratory syncytial virus are described. Core template modification, analysis of antiviral activity, physicochemistry and optimisation of properties led to the thiazole-imidazole 13, that showed a good potency and pharmacokinetic profile in the rat.